PatientsHCP
This site is for US Health Care Professionals only

ENTRESTO® is designed specifically to treat heart failure (HF)1-3 

The only treatment in the HF landscape of its kind, ENTRESTO has a dual MOA that targets 2 complementary HF pathways1-3 
Dual MOA
*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1

Important Safety Information

BOXED WARNING: FETAL TOXICITY

  • When pregnancy is detected, discontinue ENTRESTO as soon as possible
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus

ENTRESTO is contraindicated in patients with hypersensitivity to any component...

Indication

ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.

LVEF is a variable measure, so use clinical judgment in deciding whom to treat.

Click or scroll to see IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING AND INDICATION

Definitions  
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; MOA, mechanism of action; RAS, renin-angiotensin system. 

References 
1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
2. Hasenfuss G, Mann DL. Pathophysiology of heart failure. In: Mann DL, Zipes DP, Libby P, Bonow RO, eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Elsevier Saunders; 2015:1-116. 
3. Hilal-Dandan R. Renin and angiotensin. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. McGraw-Hill; 2011:721-744.